Epithelioid sarcoma in patients with rhabdoid tumor predisposition syndrome (RTPS): A novel cancer in the RTPS spectrum
Neuro-Oncology Pediatrics · 2025
DOI: 10.1093/neuped/wuaf013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Pediatrics, 2025. Verfasst von Meziane Brizini und 11 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Rhabdoid tumor predisposition syndrome (RTPS) is characterized by germline biallelic loss of SMARCB1 (RTPS1) or SMARCA4 genes, leading to early-onset tumors primarily in the brain and kidneys. Epithelioid sarcoma (EpS) is a rare malignant soft tissue sarcoma in children and young adults, characterized by loss of nuclear SMARCB1 expression. Here, we describe survivors of atypical teratoid rhabdoid tumors (ATRT) with RTPS1 who developed EpS during follow-up.
Methods
Data were collected through a retrospective chart review of 4 patients with RTPS and ATRT diagnosed with EpS during routine follow-up. A literature review on RTPS and EpS was also conducted.
Results
All 4 patients were diagnosed with ATRT and RTPS1 in infancy and treated with surgery, high-dose chemotherapy, and autologous stem cell transplantation. Relapse occurred in 3 of the 4 patients, with 2 patients undergoing surgery followed by focal radiation. EpS was diagnosed at regular follow-up, with patients presenting with multiple skin lesions in their extremities (hands, fingers). Histopathological analysis confirmed EpS with characteristic loss of SMARCB1 expression. Staging scans showed no evidence of disseminated disease. All 4 patients underwent surgical excision with negative margins, and 2 patients experienced multiple local recurrences managed with wide surgical excision. A literature review identified 1 additional case of RTPS1 with metachronous ATRT and late-onset EpS.
Conclusions
Our findings, supported by literature review, suggest that EpS is a primary malignancy within the RTPS1 cancer spectrum. Recognizing this predisposition is critical for implementing appropriate long-term surveillance and early intervention strategies in patients with RTPS1.
Zitieren
APA
Brizini, M., Raghuram, N., Chapman, S., Shawyer, A., Min, S. L., Wilkes, C., Hamza, S., Nathan, P., Chen, H., Huang, A., Lafay-Cousin, L., & Vanan, M. I. (2025). Epithelioid sarcoma in patients with rhabdoid tumor predisposition syndrome (RTPS): A novel cancer in the RTPS spectrum. Neuro-Oncology Pediatrics. https://doi.org/10.1093/neuped/wuaf013
Vancouver
Brizini M, Raghuram N, Chapman S, Shawyer A, Min SL, Wilkes C, et al. Epithelioid sarcoma in patients with rhabdoid tumor predisposition syndrome (RTPS): A novel cancer in the RTPS spectrum. Neuro-Oncology Pediatrics. 2025. doi:10.1093/neuped/wuaf013
BibTeX
@article{Brizini2025,
author = {Brizini, Meziane and Raghuram, Nikhil and Chapman, Stacy and Shawyer, Anna and Min, Suyin Lum and Wilkes, Courtney and Hamza, Sate and Nathan, Paul and Chen, Haying and Huang, Annie and Lafay-Cousin, Lucie and Vanan, Magimairajan Issai},
title = {Epithelioid sarcoma in patients with rhabdoid tumor predisposition syndrome (RTPS): A novel cancer in the RTPS spectrum},
journal = {Neuro-Oncology Pediatrics},
year = {2025},
doi = {10.1093/neuped/wuaf013}
}
EUVIMED